Source link : https://www.newshealth.biz/health-news/cendakimab-clears-skin-in-adults-with-atopic-dermatitis/
TOPLINE: Treatment with cendakimab, an investigational anti–interleukin-13 monoclonal antibody administered subcutaneously, is well tolerated and reduces the severity of atopic dermatitis (AD) and pruritus in adults with moderate to severe AD. METHODOLOGY: In a multinational, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2 study of cendakimab, researchers evaluated 221 patients with moderate to severe AD (mean age, […]
Author : News Health
Publish date : 2024-07-18 12:43:14
Copyright for syndicated content belongs to the linked Source.